Proactiveinvestors recommends

Additional Information

Market:	ASX
Sector:	Pharma & Biotech
EPIC:	POH
Latest Price:	0.20 (0.00%)
52-week High:	0.21
52-week Low:	0.10
Market Cap:	164.72M

1 year chart

1 day chart

Phosphagenics Limited

Phosphagenics (ASX: POH) is a Melbourne-based biotechnology company. Its core technology is built around the science and application of TPM™ delivery systems. This system enables transdermal delivery of proven pharmaceutical actives and enhances dermal delivery of pharmaceutical, cosmeceutical and nutraceutical actives.

Phosphagenics initiates Phase 1B clinical trial for patented oxycodon patch

Wednesday, December 02, 2009

Dual-listed Phosphagenics (ASX: POH; OTCQX: PPGNY) has initiated a Phase 1B clinical trial for its patented oxycodone/TPM (Targeted Penetration Matrix) transdermal patch systems.

The clinical trial consists of a pharmacokinetic study in twenty healthy volunteers at the Royal Adelaide Hospital.

The primary objective of the Company’s Phase 1B clinical trial is to compare two transdermal patch candidates, a matrix and reservoir system, to deliver oxycodone.

The results of the Phase 1B trial, scheduled to be completed by early 2010.

It will determine which of the two patch systems is best suited for commercial development.

The best candidate will be advanced into Phase II/III oxycodone clinical trials scheduled for 2010.

Phosphagenics’ chief operating officer, Dr Esra Ogru, said the TPM/oxycodone patch system appears potentially suitable for chronic pain management.

“The results of our first trial earlier this year were a world first and were suggestive of the potential for the TPM system to change the way in which chronic pain could be treated in the future,” she said.

“Currently, patients treated with oral oxycodone obtain pain relief for only a short period of time. The earlier human trial conducted by Phosphagenics, indicates that our oxycodone patch may provide sustained drug delivery for a matter of days.

Phosphagenics aims to become the first company to offer chronic pain sufferers an oxycodone patch that will provide sustained pain relief. In a clinical trial conducted earlier this year on 50 subjects, Phosphagenics was able to demonstrate that its formulation did not cause sensitisation or irritation, one of the major barriers preventing the use of most opioids in topical delivery systems.

US sales of oxycodone, one of the leading drugs for pain management, exceed US$1.5 billion annually.

Recently, the company raised $7 million via an underwritten share purchase plan at 9.2 cents a share.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.